Published in J Biol Chem on November 24, 2000
Structural insights into the assembly and activation of IL-1β with its receptors. Nat Immunol (2010) 1.32
Structure of IL-33 and its interaction with the ST2 and IL-1RAcP receptors--insight into heterotrimeric IL-1 signaling complexes. Structure (2009) 1.24
Structural insights into the interaction of IL-33 with its receptors. Proc Natl Acad Sci U S A (2013) 1.09
Subversion of cytokine networks by virally encoded decoy receptors. Immunol Rev (2012) 0.98
Design of a superior cytokine antagonist for topical ophthalmic use. Proc Natl Acad Sci U S A (2013) 0.84
Identification of potential small molecule allosteric modulator sites on IL-1R1 ectodomain using accelerated conformational sampling method. PLoS One (2015) 0.78
The use of an IL-1 receptor antagonist peptide to control inflammation in the treatment of corneal limbal epithelial stem cell deficiency. Biomed Res Int (2015) 0.78
Comparative analysis of receptor binding by chicken and human interleukin-1β. J Mol Model (2010) 0.77
Conformational Sampling and Binding Site Assessment of Suppression of Tumorigenicity 2 Ectodomain. PLoS One (2016) 0.75
Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor. Nature (1990) 5.86
Secretory leukocyte protease inhibitor: a human saliva protein exhibiting anti-human immunodeficiency virus 1 activity in vitro. J Clin Invest (1995) 2.95
Lipopolysaccharide induces disseminated endothelial apoptosis requiring ceramide generation. J Exp Med (1997) 2.21
Interleukin 1 receptor antagonist is a member of the interleukin 1 gene family: evolution of a cytokine control mechanism. Proc Natl Acad Sci U S A (1991) 1.97
An acute infection model for Mycobacterium intracellulare disease using beige mice: preliminary results. Am Rev Respir Dis (1983) 1.90
Crystal structure of the type-I interleukin-1 receptor complexed with interleukin-1beta. Nature (1997) 1.83
Interleukin-1 (IL-1) receptor antagonist binds to the 80-kDa IL-1 receptor but does not initiate IL-1 signal transduction. J Biol Chem (1991) 1.78
Release of superoxide anion from resident and activated mouse peritoneal macrophages infected with Mycobacterium intracellulare. Am Rev Respir Dis (1984) 1.55
Different roles of tumour necrosis factor alpha and interleukin 1 in murine streptococcal cell wall arthritis. Cytokine (1998) 1.43
Greatly accelerated lymphadenopathy and autoimmune disease in lpr mice lacking tumor necrosis factor receptor I. J Immunol (1996) 1.43
LPS-induced liver injury in D-galactosamine-sensitized mice requires secreted TNF-alpha and the TNF-p55 receptor. Am J Physiol Regul Integr Comp Physiol (2000) 1.39
Disparate roles for TNF-alpha and Fas ligand in concanavalin A-induced hepatitis. J Immunol (1998) 1.38
Reduction of arthritis and pneumonitis in motheaten mice by soluble tumor necrosis factor receptor. Arthritis Rheum (1998) 1.37
Combination benefit of treatment with the cytokine inhibitors interleukin-1 receptor antagonist and PEGylated soluble tumor necrosis factor receptor type I in animal models of rheumatoid arthritis. Arthritis Rheum (2000) 1.31
Adenosine and a related carbocyclic nucleoside analogue selectively inhibit tumor necrosis factor-alpha production and protect mice against endotoxin challenge. J Immunol (1993) 1.30
Crystallographic evidence for dimerization of unliganded tumor necrosis factor receptor. J Biol Chem (1995) 1.28
Defective localization of the NADPH phagocyte oxidase to Salmonella-containing phagosomes in tumor necrosis factor p55 receptor-deficient macrophages. Proc Natl Acad Sci U S A (2001) 1.24
Lipopolysaccharide and D-galactosamine-induced hepatic injury is mediated by TNF-alpha and not by Fas ligand. Am J Physiol Regul Integr Comp Physiol (2000) 1.17
Defective maintenance of T cell tolerance to a superantigen in MRL-lpr/lpr mice. J Exp Med (1992) 1.07
Inhibition of tumor necrosis factor alpha decreases inflammation and prolongs adenovirus gene expression in lung and liver. Hum Gene Ther (1998) 1.06
Induction of specific T cell tolerance by Fas ligand-expressing antigen-presenting cells. J Immunol (1999) 1.06
Activation of adenosine A3 receptors on macrophages inhibits tumor necrosis factor-alpha. Eur J Pharmacol (1996) 1.06
Interferon-gamma-induced priming for secretion of superoxide anion and tumor necrosis factor-alpha declines in macrophages from aged rats. FASEB J (1990) 1.03
Mapping receptor binding sites in interleukin (IL)-1 receptor antagonist and IL-1 beta by site-directed mutagenesis. Identification of a single site in IL-1ra and two sites in IL-1 beta. J Biol Chem (1995) 1.01
A mutation at histidine residue 135 of toxic shock syndrome toxin yields an immunogenic protein with minimal toxicity. Infect Immun (1995) 0.99
Adeno-associated virus production of soluble tumor necrosis factor receptor neutralizes tumor necrosis factor alpha and reduces arthritis. Hum Gene Ther (2000) 0.99
Carbocyclic nucleosides as inhibitors of human tumor necrosis factor-alpha production: effects of the stereoisomers of (3-hydroxycyclopentyl)adenines. J Med Chem (1996) 0.98
Prevention of age-related T cell apoptosis defect in CD2-fas-transgenic mice. J Exp Med (1995) 0.98
Increased leptin expression in mice with bacterial peritonitis is partially regulated by tumor necrosis factor alpha. Infect Immun (1998) 0.97
Antiarthritic activity of soluble tumor necrosis factor receptor type I forms in adjuvant arthritis: correlation of plasma levels with efficacy. J Rheumatol (1999) 0.97
Role of interferon-gamma in counteracting the suppressive effects of transforming growth factor-beta 2 and glucocorticoids on the production of tumor necrosis factor-alpha. J Leukoc Biol (1990) 0.97
Phase I/II trial of recombinant methionyl human tumor necrosis factor binding protein PEGylated dimer in patients with active refractory rheumatoid arthritis. J Rheumatol (2000) 0.96
Combination benefit of PEGylated soluble tumor necrosis factor receptor type I (PEG sTNF-RI) and dexamethasone or indomethacin in adjuvant arthritic rats. Inflamm Res (1999) 0.95
Effects of PEGylated soluble tumor necrosis factor receptor type I (PEG sTNF-RI) alone and in combination with methotrexate in adjuvant arthritic rats. Clin Exp Rheumatol (1999) 0.95
Glucocorticoid-induced, caspase-dependent organ apoptosis early after burn injury. Am J Physiol Regul Integr Comp Physiol (2000) 0.93
Herpes simplex virus type 2 infection induced apoptosis in peritoneal macrophages independent of Fas and tumor necrosis factor-receptor signaling. Viral Immunol (1999) 0.92
X-ray structure of interleukin-1 receptor antagonist at 2.0-A resolution. J Biol Chem (1994) 0.92
Caspase-3-dependent organ apoptosis early after burn injury. Ann Surg (1999) 0.91
Apoptosis mediated by Fas but not tumor necrosis factor receptor 1 prevents chronic disease in mice infected with murine cytomegalovirus. J Clin Invest (1998) 0.91
Secretory leukocyte protease inhibitor prevents allergen-induced pulmonary responses in animal models of asthma. J Pharmacol Exp Ther (1999) 0.90
Pharmacokinetics, immunogenicity, and efficacy of dimeric TNFR binding proteins in healthy and bacteremic baboon. J Appl Physiol (1985) (1998) 0.90
Use of recombinant human soluble TNF receptor in anorectic tumor-bearing rats. Am J Physiol (1999) 0.90
Inhibition of allergen-induced pulmonary responses by the selective tryptase inhibitor 1,5-bis-[4-[(3-carbamimidoyl-benzenesulfonylamino)-methyl]-phenoxy]-pen tane (AMG-126737). Biochem Pharmacol (1999) 0.88
Involvement of 26-kDa cell-associated TNF-alpha in experimental hepatitis and exacerbation of liver injury with a matrix metalloproteinase inhibitor. J Immunol (1997) 0.88
A carbocyclic nucleoside analogue is a TNF-alpha inhibitor with immunosuppressive action: role of prostaglandin E2 and protein kinase C and comparison with pentoxifylline. Cell Immunol (1998) 0.86
Adenosine A3 receptor agonists inhibit murine macrophage tumor necrosis factor-alpha production in vitro and in vivo. Cell Mol Biol (Noisy-le-grand) (1997) 0.86
Phenotype of genetically regulated thymic involution in young BXD RI strains of mice. Scand J Immunol (2006) 0.85
Apoptosis defects analyzed in TcR transgenic and fas transgenic lpr mice. Int Rev Immunol (1994) 0.85
Interleukin-1 receptor antagonist (IL-1ra) as a probe and as a treatment for IL-1 mediated disease. Int J Immunopharmacol (1992) 0.84
Increased susceptibility of fas mutant MRL-lpr/lpr mice to staphylococcal enterotoxin B-induced septic shock. J Immunol (1995) 0.83
Crystals and a low resolution structure of interleukin-2. J Biol Chem (1987) 0.83
Seeing double: crystal structures of the type I TNF receptor. J Mol Recognit (1997) 0.82
Visualizing CD4 T-cell migration into inflamed skin and its inhibition by CCR4/CCR10 blockades using in vivo imaging model. Br J Dermatol (2009) 0.82
Defective Fas ligand-mediated apoptosis predisposes to development of a chronic erosive arthritis subsequent to Mycoplasma pulmonis infection. Arthritis Rheum (2001) 0.81
Glucocorticoid and Fas ligand induced mucosal lymphocyte apoptosis after burn injury. J Trauma (2000) 0.81
Soluble Fas gene therapy protects against Fas-mediated apoptosis of hepatocytes but not the lethal effects of Fas-induced TNF-alpha production by Kupffer cells. Cell Death Differ (2002) 0.81
Genetic determinants of lipopolysaccharide and D-galactosamine-mediated hepatocellular apoptosis and lethality. J Endotoxin Res (2001) 0.81
Autoimmune disease results from multiple interactive defects in apoptosis induction molecules and signaling pathways. Behring Inst Mitt (1996) 0.79
In vivo effects of recombinant interferon-gamma: augmentation of endotoxin-induced necrosis of tumors and priming of macrophages for tumor necrosis factor-alpha production. Cancer Lett (1990) 0.79
Tumor necrosis factor (TNF)-alpha-induced interleukin-8 in human blood cultures discriminates neutralization by the p55 and p75 TNF soluble receptors. J Infect Dis (2000) 0.78
Development of a novel, nonimmunogenic, soluble human TNF receptor type I (sTNFR-I) construct in the baboon. J Appl Physiol (1985) (2001) 0.78
Specific transcriptional inhibition of bone marrow-derived macrophage tumor necrosis factor-alpha gene expression and protein production using novel enantiomeric carbocyclic nucleoside analogues. J Pharmacol Exp Ther (1995) 0.78
Potent selective nonpeptidic inhibitors of human lung tryptase. Proc Natl Acad Sci U S A (1999) 0.78
Murine models of autoimmunity: T-cell and B-cell defects. Curr Opin Rheumatol (1992) 0.77
Treatment of rheumatoid arthritis with PEGylated recombinant human soluble tumour necrosis factor receptor type I: a clinical update. Ann Rheum Dis (2000) 0.77
Murine models of autoimmune disease. Curr Opin Rheumatol (1992) 0.77
A fas antigen receptor mutation allows development of toxic shock syndrome toxin-1-induced lethal shock in V beta 8.2 T-cell receptor transgenic mice. Pathobiology (1995) 0.76
IL-1ra: properties and uses of an interleukin-1 receptor antagonist. Agents Actions Suppl (1991) 0.76
T cell influence on superantigen-induced arthritis in MRL-lpr/lpr mice. Arthritis Rheum (1994) 0.75
TNF-alpha blockade by a dimeric TNF type I receptor molecule selectively inhibits adaptive immune responses. Immunopharmacol Immunotoxicol (2000) 0.75
The respiratory burst in activated macrophages: studies of its molecular basis and evidence for downregulation in chronic infection. Adv Exp Med Biol (1988) 0.75
Autoimmunity due to defective Nur77, Fas, and TNF-RI apoptosis. Adv Exp Med Biol (1996) 0.75
Effects of cell isolation procedures and radioligand selection on the characterization of human leukocyte beta-adrenergic receptors. Biochem Pharmacol (1987) 0.75